Lundbeck reports positive phase II proof-of-concept results for migraine drug
On Wednesday, pharmaceutical firm Lundbeck announced that a preventive migraine treatment, which the company says could be a potential new therapeutic option, met all endpoints in a mid-stage trial.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.